However, genome-wide copy number variations (CNV), structural aberrations characteristic of advanced prostate cancer (PCa) [12–14] and reflective of genomic instability, are underexplored in the context of PSMA RLT, despite their demonstrated value as predictors of taxane chemotherapy responses and outcomes [15, 16]. The gene discussed is FOLH1; the disease is Familial prostate cancer.